-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Generic drugs can replace the original research drugs to play the same clinical role, reduce medical expenses, improve drug accessibility, and improve the level of medical service.
In recent years, with the promotion of policies such as the normalization of centralized procurement and the consistency evaluation of generic drugs, pharmaceutical companies are actively promoting the review work, and the competition is fierc.
The data shows that as of the end of July this year, the total number of acceptances for the consistency evaluation of generic drugs still reached 4,112, and 2,603 were accepted, and 2,205 were deemed to have passe.
It can be said that the battle for the consistency evaluation of generic drugs has already started, and pharmaceutical companies are competing for the first, or squeezed into the top thre.
So, which pharmaceutical companies have won the majority of the first varieties? Judging from the public information of various pharmaceutical companies, pharmaceutical companies such as Yangtze River, Qilu, China Biopharmaceuticals, CSPC, and Hengrui are all active in competing for the first imitatio.
According to data from Mine.
com, as of April 22, 105 varieties of Yangzijiang Pharmaceutical have been reviewed, of which 25 won the first on.
The 105 reviewed varieties are mainly concentrated in the therapeutic fields of systemic anti-infective drugs, anti-tumor and immunomodulatory agents, digestive system and metabolic drug.
Qilu Pharmaceutical has always been in an active position in the field of generic drug consistency evaluatio.
As of the end of April this year, more than 100 products of the company have passed or are deemed to have passed the consistency evaluation of generic drugs, of which 43 have won the first domestic produc.
These 100 over-reviewed drugs are mainly concentrated in the fields of anti-tumor and immunomodulatory agents, systemic anti-infective drugs, and nervous system drug.
As of April 22, Sino Biopharmaceutical has 85 varieties that have passed/deemed to have passed the evaluation, of which 32 have passed the evaluation for the first tim.
The varieties that have been reviewed are mainly concentrated in the fields of anti-tumor and immunomodulatory agents, digestive system and metabolic drugs, and systemic anti-infective drug.
CSPC is also actively working on the consistency evaluation of generic drug.
According to data from Mine.
com, as of August 3, CSPC has passed/deemed to pass the consistency evaluation of 78 varieties, of which 21 varieties have won the first plac.
Home, 78 varieties cover 8 therapeutic categories, mainly focusing on systemic anti-infective drugs, nervous system drugs, anti-tumor and immunomodulators, digestive system and metabolic drug.
In addition, Hengrui Medicine currently has 60 varieties that have passed the consistency evaluation of generic drugs, of which 31 have won the first on.
Since 2022 alone, Hengrui has won 8 first/exclusive review varietie.
Its 31 varieties cover 12 therapeutic categories, mainly focusing on anti-tumor and immunomodulatory agents, nervous system drugs, cardiovascular system drugs and other therapeutic field.
For pharmaceutical companies, the over-evaluation of varieties is beneficial to the company's follow-up developmen.
According to the relevant national policies and regulations, appropriate support will be given in terms of medical insurance payment for the varieties of drugs that have been evaluated, and medical institutions should give priority to purchase and use them in clinical practic.
It is worth mentioning that in addition to promoting the over-evaluation of generic drugs, many pharmaceutical companies have increased investment in research and development of innovative drugs in recent year.
Taking Qilu Pharmaceutical as an example, in the past five years, the company's R&D investment has increased from 2 billion yuan in 2017 to 32 billion yuan in 2021, and the proportion of R&D investment in sales revenue has continued to increase from 6% to nearly 10.
For another example, Qilu Pharmaceutical's total R&D investment in 2021 will reach 82 billion yuan, accounting for 142% of the group's revenu.
Among them, the R&D investment of innovative drugs and biological drugs has accounted for more than 70.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
In recent years, with the promotion of policies such as the normalization of centralized procurement and the consistency evaluation of generic drugs, pharmaceutical companies are actively promoting the review work, and the competition is fierc.
The data shows that as of the end of July this year, the total number of acceptances for the consistency evaluation of generic drugs still reached 4,112, and 2,603 were accepted, and 2,205 were deemed to have passe.
It can be said that the battle for the consistency evaluation of generic drugs has already started, and pharmaceutical companies are competing for the first, or squeezed into the top thre.
So, which pharmaceutical companies have won the majority of the first varieties? Judging from the public information of various pharmaceutical companies, pharmaceutical companies such as Yangtze River, Qilu, China Biopharmaceuticals, CSPC, and Hengrui are all active in competing for the first imitatio.
According to data from Mine.
com, as of April 22, 105 varieties of Yangzijiang Pharmaceutical have been reviewed, of which 25 won the first on.
The 105 reviewed varieties are mainly concentrated in the therapeutic fields of systemic anti-infective drugs, anti-tumor and immunomodulatory agents, digestive system and metabolic drug.
Qilu Pharmaceutical has always been in an active position in the field of generic drug consistency evaluatio.
As of the end of April this year, more than 100 products of the company have passed or are deemed to have passed the consistency evaluation of generic drugs, of which 43 have won the first domestic produc.
These 100 over-reviewed drugs are mainly concentrated in the fields of anti-tumor and immunomodulatory agents, systemic anti-infective drugs, and nervous system drug.
As of April 22, Sino Biopharmaceutical has 85 varieties that have passed/deemed to have passed the evaluation, of which 32 have passed the evaluation for the first tim.
The varieties that have been reviewed are mainly concentrated in the fields of anti-tumor and immunomodulatory agents, digestive system and metabolic drugs, and systemic anti-infective drug.
CSPC is also actively working on the consistency evaluation of generic drug.
According to data from Mine.
com, as of August 3, CSPC has passed/deemed to pass the consistency evaluation of 78 varieties, of which 21 varieties have won the first plac.
Home, 78 varieties cover 8 therapeutic categories, mainly focusing on systemic anti-infective drugs, nervous system drugs, anti-tumor and immunomodulators, digestive system and metabolic drug.
In addition, Hengrui Medicine currently has 60 varieties that have passed the consistency evaluation of generic drugs, of which 31 have won the first on.
Since 2022 alone, Hengrui has won 8 first/exclusive review varietie.
Its 31 varieties cover 12 therapeutic categories, mainly focusing on anti-tumor and immunomodulatory agents, nervous system drugs, cardiovascular system drugs and other therapeutic field.
For pharmaceutical companies, the over-evaluation of varieties is beneficial to the company's follow-up developmen.
According to the relevant national policies and regulations, appropriate support will be given in terms of medical insurance payment for the varieties of drugs that have been evaluated, and medical institutions should give priority to purchase and use them in clinical practic.
It is worth mentioning that in addition to promoting the over-evaluation of generic drugs, many pharmaceutical companies have increased investment in research and development of innovative drugs in recent year.
Taking Qilu Pharmaceutical as an example, in the past five years, the company's R&D investment has increased from 2 billion yuan in 2017 to 32 billion yuan in 2021, and the proportion of R&D investment in sales revenue has continued to increase from 6% to nearly 10.
For another example, Qilu Pharmaceutical's total R&D investment in 2021 will reach 82 billion yuan, accounting for 142% of the group's revenu.
Among them, the R&D investment of innovative drugs and biological drugs has accounted for more than 70.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
